MedDataX Logo

Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines

NCT ID: NCT06212960

Last Updated: 2024-04-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-28

Study Completion Date

2024-03-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the safety of 12-week administration of DWP712 inj. in subjects with moderate to severe glabellar lines.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines

NCT07013279

Glabellar Lines
NOT_YET_RECRUITING PHASE3

Efficacy and Safety of DWP450 Compared With Botox in Moderate to Severe Glabellar Line

NCT01629875

Moderate to Severe Glabellar Line
COMPLETED PHASE3

To Evaluate the Safety and Efficacy of Botulax® Are Not Inferior to Those of Botox® in the Treatment of Glabellar Lines

NCT01791920

Skin Aging
COMPLETED PHASE3

Treatment of Moderate to Severe Glabellar Lines (BMI2006)

NCT05531968

Glabellar Lines
COMPLETED PHASE3

The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines

NCT05364580

Glabellar Frown Lines
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glabellar Lines

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DWP712

Patients were intramuscularly injected (IM) with a total of 20U of DWP712 in 5 places of 0.1 mL (4 U/0.1 mL) each on the glabellar line.

Group Type EXPERIMENTAL

DWP712

Intervention Type BIOLOGICAL

Clostridium botulinum Toxin

Botox®

Patients were intramuscularly injected (IM) with a total of 20U of BOTOX® in 5 places of 0.1 mL (4 U/0.1 mL) each on the glabellar line.

Group Type ACTIVE_COMPARATOR

BOTOX®

Intervention Type BIOLOGICAL

Clostridium botulinum Toxin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DWP712

Clostridium botulinum Toxin

Intervention Type BIOLOGICAL

BOTOX®

Clostridium botulinum Toxin

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects with facial wrinkle scale (FWS) score of visual appearance of glabellar lines ≥2 (moderate) at maximum frown as assessed by the investigator at screening

Exclusion Criteria

\-
Minimum Eligible Age

19 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Beom Joon Kim, MD, Ph.D

Role: PRINCIPAL_INVESTIGATOR

Chung-Ang University Hosptial, Chung-Ang University College of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chung-Ang University Hosptial

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DW_DWP712101

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar Lines
NCT01237977 COMPLETED PHASE3
Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines
NCT02236312 COMPLETED PHASE2
Evaluation Onset Time of DWP450-004 and Safety in Moderate-severe Glabellar Lines
NCT02568150 COMPLETED PHASE4
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I
NCT02677298 COMPLETED PHASE3
Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines
NCT05059587 COMPLETED PHASE3
Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial
NCT05804656 COMPLETED PHASE3
A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
NCT05217355 COMPLETED PHASE2
Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
NCT03014622 COMPLETED PHASE3
Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
NCT03014635 COMPLETED PHASE3
A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines
NCT05463965 COMPLETED PHASE3
Treatment of Moderate to Severe Glabellar Lines
NCT04249583 COMPLETED PHASE3
Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines
NCT03004248 COMPLETED PHASE3
Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines
NCT01391312 COMPLETED PHASE4
The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines
NCT02961673 COMPLETED PHASE1/PHASE2
Safety and Efficacy Study of ATGC-100 for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects
NCT03970876 COMPLETED PHASE1/PHASE2
Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines
NCT04143815 COMPLETED PHASE2
Efficacy and Safety of DWP450 for the Treatment of Crows Feet Lines
NCT02882893 UNKNOWN PHASE2/PHASE3
Safety and Efficacy of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines
NCT05292638 COMPLETED PHASE1
The Efficacy and Safety of Protoxin in Subjects With Moderate to Severe Glabellar Lines
NCT06124794 COMPLETED PHASE3
Evaluate the Safety and Efficacy of Botulax® as Compared to Botox® in Subject With Moderate to Severe Crow's Feet Lines
NCT03408236 COMPLETED PHASE3
Efficacy and Safety Study of MT10109L in the Treatment of Glabella Line(Including a Preliminary Study to Evaluate Safety of MT10109L)
NCT03894748 COMPLETED PHASE2/PHASE3
Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
NCT03736928 COMPLETED PHASE2
A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines
NCT06308198 COMPLETED PHASE3
Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
NCT04225260 COMPLETED PHASE3
Efficacy and Safety of DWP450 for Treating Crows Feet Lines(CFL) in Combination With Glabellar Lines(Extension Study)
NCT03184363 UNKNOWN PHASE3